Clinical trials: Advanced or Metastatic Solid Tumor
Solid Tumor, Cancer Metastatic
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
To evaluate CAN1012(Selective TLR7 agonist) when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.
- Trial name
- NCT04987112
- Testing
- CAN1012
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- CanWell Pharma Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic solid tumors.
- Trial name
- NCT05458219
- Testing
- IBI343, FOLFIRINOX/mFOLFIRINOX, mFOLFOX
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 470 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Solid Tumors
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK41959 when given orally in patients with MTAP Deletion locally advanced or metastatic Solid Tumors.
- Trial name
- NCT06968572
- Testing
- HSK41959
- Where
- 3 sites in China
- Volunteers
- 245 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Advanced Solid Tumours, Endometrial Cancer
A Phase 1 Study of [225Ac]-FPI-1434 Injection
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic…
- Conditions
- Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer
- Trial name
- NCT03746431
- Testing
- [111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 78 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Advanced Cancer
Phase 1 Study of Mesothelin-ADC
The purpose of this study is to assess the safety and tolerability of Mesothelin-ADC in subjects with advanced and/or metastatic solid tumors.
- Trial name
- NCT02884726
- Testing
- BMS-986148
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Adult, NSCLC
Study to Evaluate D-1553 in Subjects With Solid Tumors
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with…
- Conditions
- Solid Tumor, Adult, NSCLC, CRC
- Trial name
- NCT04585035
- Testing
- D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 180 people
- Sponsor
- InventisBio Co., Ltd
Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2…
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian Cancer
- Trial name
- NCT07612891
- Testing
- INV-6452
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
This study will investigate the safety and tolerability of combination therapy with MK-2206 and AZD6244 (selumetinib) and determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) for this drug combination in…
- Trial name
- NCT01021748
- Testing
- MK-2206, AZD6244
- Volunteers
- 63 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A*02:01-positive and MAGE-A1-positive advanced solid tumors.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07583316
- Testing
- CRPA1A2
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Melanoma, Non Small Cell Lung Cancer
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
- Trial name
- NCT03340506
- Testing
- dabrafenib, trametinib
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
This is a Phase I, open-label, dose escalation study of LNP3794 (BI3011441) in subjects with NRAS/KRAS mutated advanced or metastatic refractory solid tumors.
- Trial name
- NCT05187858
- Testing
- LNP3794
- Where
- 4 sites in Belgium, Netherlands and 1 more
- Volunteers
- 15 people
- Sponsor
- Lupin Ltd.
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors.
- Trial name
- NCT01325558
- Testing
- ALT-836 in combination with gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Altor BioScience
Locally Advanced or Metastatic Pancreatic Cancer With
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid…
- Trial name
- NCT07296341
- Testing
- HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine, HRS-4642;nab-paclitaxel; gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Advanced or Metastatic Solid Tumors
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
This is a phase I, open-label, multi-center, dose escalation and expansion study in advanced or metastatic solid tumor patients.
- Trial name
- NCT07260305
- Testing
- KGX101 injection, Envafolimab
- Where
- 3 sites in China
- Volunteers
- 57 people
- Sponsor
- Kangabio AUSTRALIA LTD PTY
Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid…
- Trial name
- NCT01107522
- Testing
- CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tactical Therapeutics, Inc.
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC)
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors…
- Conditions
- Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT07020117
- Testing
- [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
- Where
- 14 sites in United States
- Volunteers
- 150 people
- Sponsor
- Aktis Oncology, Inc.
Glioma, Glioma, Malignant
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422.
- Conditions
- Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors
- Trial name
- NCT04541225
- Testing
- NUV-422
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Nuvation Bio Inc.
Unspecified Adult Solid Tumor, Protocol Specific
DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as DJ-927 and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00077077
- Testing
- DJ-927, capecitabine
- Where
- 3 sites in United States
- Sponsor
- Daiichi Sankyo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.